Insider Trading November 16, 2026 08:46 PM

Halozyme CEO Helen Torley Offloads $6 Million in Stock Under Pre-Set Trading Plan

The sale of 60,000 shares coincided with the exercise of options, leaving Torley with direct ownership of 767,780 shares.

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
HALO

Helen Torley, President and CEO of Halozyme Therapeutics, sold approximately $6.0 million in common stock between November 12 and November 16, 2026, at prices ranging from $96.440 to $101.940 per share. The transactions were executed under a Rule 10b5-1 trading plan adopted on December 3, 2025. Concurrently, Torley exercised options to acquire 60,000 shares at prices between $16.65 and $18.41, totaling about $1.04 million. Following these moves, she directly owns 767,780 shares. The sales come after Halozyme reported strong third-quarter 2026 results, beating estimates on both earnings and revenue and raising full-year guidance. However, the stock has faced pressure amid concerns over valuation, litigation, and growth pace, with Morgan Stanley downgrading the shares to Equalweight while TD Cowen maintained a Buy rating.

Halozyme CEO Helen Torley Offloads $6 Million in Stock Under Pre-Set Trading Plan
HALO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CEO Helen Torley sold 60,000 shares for approximately $6.0 million under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025.
  • The sales coincided with the exercise of 60,000 options at prices between $16.65 and $18.41, generating proceeds of about $1.04 million for Torley.
  • Following the transactions, Torley directly owns 767,780 shares, and the insider activity comes after Halozyme's strong Q3 2026 results and mixed analyst actions.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) disclosed that its President and Chief Executive Officer, Helen Torley, sold common stock valued at approximately $6.0 million in a series of transactions last week. The sales took place between November 12 and November 16, 2026, according to the report.

Torley disposed of 60,000 shares at prices spanning $96.440 to $101.940 per share. The sales were executed pursuant to a pre-arranged trading plan adopted on December 3, 2025, under Rule 10b5-1. The shares sold were acquired following the exercise of stock options with ten-year terms expiring in February 2028 and February 2029.

In conjunction with the sales, Torley exercised options to acquire 60,000 shares of Halozyme common stock. These acquisitions totaled approximately $1.04 million, with exercise prices ranging from $16.65 to $18.41 per share. The options were part of grants made to Torley in February 2018 and February 2019.

After the reported transactions, Torley directly beneficially owns 767,780 shares of Halozyme common stock.

The insider activity follows Halozyme's third-quarter 2026 financial results, which surpassed Wall Street expectations. The company reported adjusted earnings of $2.39 per share on revenue of $492.97 million, compared to estimates of $2.28 per share and $487.13 million in revenue. Halozyme also raised its full-year guidance across several key measures.

Despite the positive earnings, the stock declined, reflecting investor concerns over valuation, litigation, and the pace of future growth. Additionally, Morgan Stanley downgraded Halozyme's stock rating to Equalweight from Overweight, citing a diversified royalty base and strengthened European intellectual property position. The firm adjusted its price target to $109, reflecting the current royalty portfolio, which is expected to peak in 2029. Meanwhile, TD Cowen reiterated a Buy rating on Halozyme, maintaining a price target of $130, and noted the recent stock pullback as a buying opportunity.

The sale by the CEO comes amid this mixed analyst sentiment and may draw attention from investors monitoring insider transactions for signals about management's confidence and valuation perceptions.

Risks

  • Insider selling could be perceived negatively by investors, potentially adding pressure on HALO shares amid existing valuation and litigation concerns.
  • Analyst downgrades, such as Morgan Stanley's move to Equalweight, may weigh on sentiment and limit upside despite TD Cowen's bullish stance.
  • The pace of future growth remains a concern, as highlighted by the stock's decline even after strong earnings and raised guidance.

More from Insider Trading

Kinetik Insider Sale: ISQ Global Fund Offloads $4.25 Million in Stock Nov 16, 2026 Saba Capital Adds $795K to BNY Mellon Strategic Municipals Stake Nov 16, 2026 Expensify Director Offloads $660,596 in Shares Across Two-Day Sale Nov 16, 2026 CorMedix CEO Joseph Todisco Purchases $391,200 in Company Shares Nov 16, 2026 Hinge Health Co-Founder Mecklenburg Offloads $24.48M in Shares Near 52-Week High Nov 16, 2026